Interpreting probiotic and combination-therapy studies in Blastocystis.

Interest in probiotic-based adjuncts to anti-protozoal therapy is justified, particularly where clinical responses to metronidazole are inconsistent. However, claims in the Blastocystis literature are frequently weakened by suboptimal design and reporting problems that make results difficult to interpret, reproduce, or translate. Here, we discuss a recently published Gut Pathogens study evaluating metronidazole, Lactobacillus probiotics, and combination therapy in vitro and in a mouse model. The core idea is plausible, but the paper illustrates recurring pitfalls that risk misleading readers: internal inconsistencies between the abstract and methods in dosing and concentrations, probiotic experiments without controls to separate parasite-specific effects from culture chemistry (vehicle and pH effects), reliance on microscopy-only burden estimates without molecular confirmation, and immunostaining results that appear internally contradictory and methodologically unclear. These issues matter because probiotic interventions can alter pH, redox status, nutrient availability, and immune status independently of any direct antiparasitic activity. Without appropriate controls, apparent "synergy" can be an artefact. We outline a minimum set of controls and reporting items that would make similar studies interpretable, including in vitro excipient- and pH-matched controls, uninfected intervention arms in vivo, blinded scoring, quantitative parasite burden as assessed by qPCR, and standard immunostaining controls. A community-wide emphasis on these basics would improve reproducibility, reduce overinterpretation, and accelerate progress toward genuine mechanistic understanding of Blastocystis in the gut ecosystem.